Featured Editorial

  1. Stability And Release Testing For Delivery Devices: Waived Or Wanted? 7/13/2026

    In this article, combination product consultant Doug Mead reports on precedent research he conducted on requests for FDA waivers on functional stability and release testing for drug delivery devices. He provides sample scenarios in the context of device design considerations for Essential Performance Requirements (EPRs) and the more recent FDA draft guidance on Essential Drug Delivery Outputs (EDDOs).

  2. Microneedles In Drug Delivery: From Bench To Patch 7/10/2026

    Let's take a closer look at the scientific principles, technological progress, and translational hurdles defining the present state of microneedle research.

  3. How Targeted Nanoparticles And Circular RNA Are Advancing CAR-T Development 7/2/2026

    To overcome the short duration of therapeutic protein expression associated with mRNA, Sail Biomedicine has developed novel endless RNA constructs. Michael Lam, Ph.D., discusses its delivery mechanisms and an outlook for future applications.

  4. Beyond The Surface: Balancing Efficacy, Safety, And Patient Experience In Ophthalmic Delivery 6/30/2026

    Ocular drug delivery faces strong barriers. Choosing between topical and intravitreal routes of administration shape efficacy, safety, and CMC design decisions. 

  5. Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression 6/29/2026

    While circular RNA platforms can enhance protein expression, developing effective delivery strategies remains the key challenge to achieving therapeutic efficacy.

  6. Biomaterials In Ophthalmology Are Reshaping Ocular Drug Delivery 6/15/2026

    Biomaterial-based ocular drug delivery systems are transforming eye care by improving efficacy, reducing treatment burden, and enabling regenerative therapies.

  7. Why Improving Drug Delivery Remains A Major Opportunity In Oncology 6/12/2026

    Engineered oncolytic viruses are emerging as a promising way to target tumors, deliver immune-stimulating payloads, and improve treatment of metastatic cancer.

  8. Crossing The Brain's Barrier: Recent Advances And What Lies Ahead 6/11/2026

    Recent FDA approvals mark a breakthrough in blood-brain barrier drug delivery, validating brain-shuttle technologies and accelerating new CNS therapies.

  9. Navigating Combination Products: Device Complexity And Software Integration 6/4/2026

    Software-enabled combination products demand early cross-functional alignment, regulatory foresight, and collaboration to avoid delays and accelerate patient access.

  10. Improving Execution Of Biological Evaluation Of Drug Delivery Devices 6/3/2026

    This article provides a framework to streamline the biological safety assessment process, reduce testing burdens, and improve patient safety for combination products.